CYTK - Cytokinetics, Incorporated
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Cytokinetics (NASDAQ: CYTK - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership. Earnings and Valuation This table compares Actinium Pharmaceuticals and
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of common stock and 40,084 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 29 employees, whose employment commenced in September and October 2026 as a material inducement to their employment.
Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients. MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Taiwan Semiconductor Manufacturing stock on September 22nd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF
Maze Therapeutics (NASDAQ: MAZE - Get Free Report) and Cytokinetics (NASDAQ: CYTK - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation. Analyst Recommendations This is a breakdown of current ratings
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM
Cytokinetics (NASDAQ: CYTK - Get Free Report) and Zai Lab (NASDAQ: ZLAB - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations. Risk and Volatility Cytokinetics has a beta of
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice
Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure.
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) EVP Fady Malik sold 3,500 shares of the firm's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $68.29, for a total value of $239,015.00. Following the transaction, the executive vice president directly owned 153,902 shares in the company, valued
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 shares of common stock and 35,025 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 23 employees, whose employment commenced in August and September 2026 as a material inducement to their employment.
Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) CEO Robert Blum sold 97,926 shares of Cytokinetics stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $69.33, for a total value of $6,789,209.58. Following the transaction, the chief executive officer owned 385,320 shares of the company's stock,
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cytokinetics, Incorporated's stock remains under pressure. At the same time, Myqorzo sales rose 427.1% quarter-over-quarter to $25.3 million in the second quarter, despite competitive pressure from Bristol Myers Squibb's Camzyos. Meanwhile, the August 28 NEJM article revealed full Phase 3 ACACIA-HCM data, in which Myqorzo showed high efficacy in treating symptomatic nonobstructive HCM, where Camzyos failed.
Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript